NASDAQ · Biotechnology

Arcturus Therapeutics Holdings Inc. (ARCT) Stock

$13.74 +6.76% NASDAQ: ARCT Healthcare

Valuation

MetricValue
Price$13.74
Market Cap$390.53M
P/E Ratio-3.91
P/B Ratio2.16
P/S Ratio15.56
EPS (TTM)$0.00
52-Week High$24.17
52-Week Low$5.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.54%
ROA-41.58%
ROCE-54.07%
Gross Margin-111.94%
Operating Margin-111.94%
Net Margin-391.90%
Debt/Equity0.13
Current Ratio6.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$206.0M$158.0M$138.0M$67.0M
Operating Profit$-203.0M$12.0M$-78.0M$-96.0M$-75.0M
Net Profit$-204.0M$9.0M$-30.0M$-81.0M$-66.0M
EPS$-7.74$0.35$-1.12$-3.00$-2.40
Op Margin-1641.3%5.9%-49.6%-69.1%-111.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$393.0M$450.0M$429.0M$344.0M$271.0M
Total Liabilities$165.0M$180.0M$151.0M$103.0M$57.0M
Cash$370.0M$392.0M$292.0M$237.0M$231.0M
Borrowings$69.0M$95.0M$30.0M$29.0M$25.0M

Latest News

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? Zacks · Jul 3, 2026 Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis MT Newswires · Jul 2, 2026 Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Business Wire · Jul 2, 2026 Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies MarketBeat · Jun 5, 2026 Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary Moby · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-135.0M$32.0M$-18.0M$-60.0M$-74.0M
Investing Cash Flow$-7.0M$-15.0M$-6.0M$-1.0M$0
Financing Cash Flow$1.0M$2.0M$3.0M$5.0M$0
Net Cash Flow$-90.0M$21.0M$-45.0M$-55.0M$-61.0M
Free Cash Flow$-138.0M$24.0M$-21.0M$-60.0M$-74.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA-2.43
FCF Yield-19.72%
Quick Ratio5.88
Interest Coverage0.00
Return 1Y-52.14%
Return 3Y-82.03%
Return 5Y-77.27%

Ownership

Insiders Held7.99%
Institutions Held80.45%
Institutions Float Held87.43%
Institutional HolderSharesReport Date
Federated Hermes, Inc.3,303,6402026-03-31
ARK Investment Management, LLC2,769,5182026-03-31
Blackrock Inc.2,613,2812026-03-31
Sumitomo Mitsui Trust Group, Inc.2,288,9352026-03-31
Amova Asset Management Americas Inc2,288,9352026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is led by CEO Joseph E. Payne, employs 174 people, headquartered in US, publicly traded since 2013.

Arcturus Therapeutics Holdings Inc. (ARCT) stock trades at $13.74 with a market capitalization of $390.53M. The stock is valued at a price-to-earnings (P/E) ratio of -3.91, price-to-book of 2.16, price-to-sales of 15.56. Over the past 52 weeks the stock has ranged between $5.50 and $24.17, and currently trades 43.2% below its 52-week high.

On profitability, Arcturus Therapeutics Holdings Inc. generates a return on equity (ROE) of -46.54%, return on capital employed of -54.07%, an operating margin of -111.94%, a net profit margin of -391.90%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides